Alpha Cognition
ACOGAlpha Cognition Inc. (TSXV: ACOG) is a clinical-stage biopharmaceutical company based in Canada. The company's primary business focus is the development of novel therapeutic products for neurodegenerative diseases. Its lead program targets the treatment of mild-to-moderate Alzheimer’s disease. The company’s most advanced candidate, ALPHA-1062, is a proprietary prodrug of galantamine. It is engineered to deliver the acetylcholinesterase inhibitor activity of galantamine while aiming to reduce the gastrointestinal side effects commonly associated with this class of drug. Alpha Cognition is conducting clinical trials to evaluate the safety and efficacy of this formulation for Alzheimer’s patients. The company’s pipeline also includes other preclinical programs intended to address neurological conditions. As a publicly traded entity on the TSX Venture Exchange under the symbol ACOG, Alpha Cognition operates within the biotechnology and neuroscience sectors. Its research and development efforts are concentrated on creating treatments for disorders characterized by cognitive decline, with Alzheimer’s disease representing its key therapeutic area of focus.
ACOG · Stock Price
Historical price data
About
Alpha Cognition Inc. (TSXV: ACOG) is a clinical-stage biopharmaceutical company based in Canada. The company's primary business focus is the development of novel therapeutic products for neurodegenerative diseases. Its lead program targets the treatment of mild-to-moderate Alzheimer’s disease. The company’s most advanced candidate, ALPHA-1062, is a proprietary prodrug of galantamine. It is engineered to deliver the acetylcholinesterase inhibitor activity of galantamine while aiming to reduce the gastrointestinal side effects commonly associated with this class of drug. Alpha Cognition is conducting clinical trials to evaluate the safety and efficacy of this formulation for Alzheimer’s patients. The company’s pipeline also includes other preclinical programs intended to address neurological conditions. As a publicly traded entity on the TSX Venture Exchange under the symbol ACOG, Alpha Cognition operates within the biotechnology and neuroscience sectors. Its research and development efforts are concentrated on creating treatments for disorders characterized by cognitive decline, with Alzheimer’s disease representing its key therapeutic area of focus.